Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics.

Ravassa S, Girerd N, Edelman F, López B, Ferreira JP, Zurkan D, José GS, Latasa I, Pellicori P, Cosmi F, Petutschnigg J, Heymans S, Brunner-La Rocca HP, Pieske B, Delles C, Clark AL, Díez J, Zannad F, Cleland JGF, González A, HOMAGE Trial Committees and Investigators

Open source

DOI: 10.1002/mco2.70634
Published: 2026 Mar
Container: MedComm
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/mco2.70634,
  title = {Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics.},
  author = {Ravassa S and Girerd N and Edelman F and López B and Ferreira JP and Zurkan D and José GS and Latasa I and Pellicori P and Cosmi F and Petutschnigg J and Heymans S and Brunner-La Rocca HP and Pieske B and Delles C and Clark AL and Díez J and Zannad F and Cleland JGF and González A and HOMAGE Trial Committees and Investigators},
  year = {2026},
  journal = {MedComm},
  doi = {10.1002/mco2.70634},
  url = {https://doi.org/10.1002/mco2.70634}
}

RIS

TY  - JOUR
TI  - Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics.
AU  - Ravassa S
AU  - Girerd N
AU  - Edelman F
AU  - López B
AU  - Ferreira JP
AU  - Zurkan D
AU  - José GS
AU  - Latasa I
AU  - Pellicori P
AU  - Cosmi F
AU  - Petutschnigg J
AU  - Heymans S
AU  - Brunner-La Rocca HP
AU  - Pieske B
AU  - Delles C
AU  - Clark AL
AU  - Díez J
AU  - Zannad F
AU  - Cleland JGF
AU  - González A
AU  - HOMAGE Trial Committees and Investigators
PY  - 2026
JO  - MedComm
DO  - 10.1002/mco2.70634
UR  - https://doi.org/10.1002/mco2.70634
ER  -

APA

S, R., N, G., F, E., B, L., JP, F., D, Z., GS, J., I, L., P, P., F, C., J, P., S, H., HP, B. R., B, P., C, D., AL, C., J, D., F, Z., JGF, C., A, G., & Investigators, H. T. C. A. (2026). Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics.. MedComm. https://doi.org/10.1002/mco2.70634

Source records

pubmed · retrieved 2026-09-25T03:40:20.533Z